EUVIMEDEUVIMED entdecken
Crossref

Efficient use of mepolizumab in children: An analysis of the economically justifiable price in Colombia

Jefferson Antonio Buendía iD, Andres Felipe Zuluaga iD

Pediatric Pulmonology · 2024

DOI: 10.1002/ppul.27269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Jefferson Antonio Buendía und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Farmacología y Toxicología, Facultad de Medicina, Grupo de Investigación en Farmacología y Toxicología, Universidad de Antioquia, Med…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Cost-Benefit Analysis, Quality-Adjusted Life Years. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Asthma imposes a crucial economic burden on health systems, especially with the incorporation of new drugs. Recently, mepolizumab has been approved to prevent exacerbations in patients with eosinophilic asthma. This study explores the economically justifiable price of mepolizumab for preventing exacerbations in children with severe asthma. Materials and Methods A model was developed using the microsimulation to estimate the quality‐adjusted costs and life years of two interventions: mepolizumab versus not applying standard treatment without mepolizumab. This analysis was made during a time horizon of 50 years and from a third‐payer perspective.

Results

Mepolizumab was cost‐effective using a WTP of U$ 19,992 per QALY, but not at a WTP of U$ 4828, U$ 5128 per QALY. The economically justifiable cost for mepolizumab in Colombia is between $33 and $350 per dose, for WTP of U$ 4828, and U$ 5128 respectively. At the current price of Mepolizumab, U$ 780 per dose, only using a WTP higher than U$ 10,300 per QALY mepolizumab will be the best alternative to no mepolizumab.

Conclusion

Our study shows that the economically justifiable cost for mepolizumab in Colombia is between $33 and $350 per dose, for WTP of 4828 and 5180 respectively. This result should encourage more studies in the region that optimize decision‐making processes when incorporating this drug into the health plans of each country.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaCost-Benefit AnalysisQuality-Adjusted Life YearsAnti-Asthmatic AgentsHumansColombiaChildAdolescentDrug Costs

Stichwörter der Autor:innen

asthmachildrencolombiacostmepolizumab

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Departamento de Farmacología y Toxicología, Facultad de Medicina, Grupo de Investigación en Farmacología y Toxicología, Universidad de Antioquia, Medellín, Colombia.
  • Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
  • Laboratorio Integrado de Medicina Especializada, School of Medicine, IPS Universitaria, University of Antioquia, Medellín, Colombia.

ORCID-Profile: Jefferson Antonio Buendía, Andres Felipe Zuluaga

Förderung

  • None

Zitieren

APA

Buendía, J. A., & Zuluaga, A. F. (2024). Efficient use of mepolizumab in children: An analysis of the economically justifiable price in Colombia. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27269

Vancouver

Buendía JA, Zuluaga AF. Efficient use of mepolizumab in children: An analysis of the economically justifiable price in Colombia. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27269

BibTeX
@article{Buenda2024,
  author = {Buendía, Jefferson Antonio and Zuluaga, Andres Felipe},
  title = {Efficient use of mepolizumab in children: An analysis of the economically justifiable price in Colombia},
  journal = {Pediatric Pulmonology},
  year = {2024},
  doi = {10.1002/ppul.27269}
}
Kostenlos starten →